# DigmBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/digmbio

- Industry: Pharmaceuticals
- Headquarters: Seongnam-si, South Korea
- Website: www.digmbio.com/
- Total disclosed funding: $8.2M
- Latest round: Series A (Mar 25, 2025)
- Investors on record: 7

## About

Based in South Korea and founded in 2020, DigmBio Inc. provides innovative therapies by combining scientific knowledge with practical experience. In March 2025, DigmBio Inc. raised KRW 12 billion in series A funding from new investors Partners Investment, Meritz Securities, Samho Green Investment, Industrial Bank of Korea, Medytox Venture Investment, Cornerstone Investment Partners, and Myriad Life Sciences. Jeongmin Kim is leading the firm as CEO as of 2025.
 
DigmBio’s focus is on developing innovative therapies in previously difficult or unaddressed medical areas. Their pipeline includes treatments aimed at a range of diseases, and they are actively engaged in research and development to bring new, viable solutions to market. The company showcases its work at major industry events, ensuring its innovative approach gains visibility within the pharmaceutical sector.

## Funding rounds

- Series A, Mar 25, 2025, $8.2M — Meritz Securities, Industrial Bank of Korea, Partners Investment, Samho Green Investment, Myriad Life Sciences, Medytox Venture Investment, Cornerstone Investment Partners

## Investors

- Meritz Securities — Series A
- Industrial Bank of Korea — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A
- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series A
- Myriad Life Sciences — Series A
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A
- Cornerstone Investment Partners (https://capitalatlas.ai/funds/cornerstone-investment-partners) — Series A